# The FDA cancelled one meeting. A $50 million company died. The drug still worked. - Date: 2026-04-06 - Category: Biotech & Life Sciences Kezar Life Sciences had a drug that worked in autoimmune hepatitis. The FDA agreed to accelerate it. The company still closed. Here is what that sequence of events reveals about regulatory risk in small biotech. ---